Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro D R
Christ Hospital Cardiovascular Research Center, Cincinnati, Ohio 45219.
Arch Intern Med. 1990 Feb;150(2):341-5.
Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was compared with cholestyramine resin in a randomized open-label 12-week multicenter study of 251 high-risk patients with familial or nonfamilial hypercholesterolemia. Simvastatin, 20 mg and 40 mg daily, produced mean reductions in total cholesterol of 26% and 33%, respectively, and reductions in low-density lipoprotein cholesterol level of 32% and 40%. Cholestyramine resin, 4 to 12 g twice daily, reduced total cholesterol and low-density lipoprotein cholesterol levels 15% and 21%, respectively. High-density lipoprotein cholesterol levels were increased 8% to 10% by all treatments. Plasma triglyceride levels were moderately decreased by simvastatin treatment, while triglyceride levels increased with cholestyramine treatment. Simvastatin was better tolerated than cholestyramine, which had numerous gastrointestinal tract side effects. No patient had a serious drug-related adverse event.
在一项针对251例家族性或非家族性高胆固醇血症高危患者的随机开放标签12周多中心研究中，将3-羟基-3-甲基戊二酰辅酶A还原酶的强效抑制剂辛伐他汀与消胆胺树脂进行了比较。每日服用20毫克和40毫克辛伐他汀，总胆固醇平均分别降低26%和33%，低密度脂蛋白胆固醇水平分别降低32%和40%。每日两次服用4至12克消胆胺树脂，总胆固醇和低密度脂蛋白胆固醇水平分别降低15%和21%。所有治疗使高密度脂蛋白胆固醇水平升高8%至10%。辛伐他汀治疗使血浆甘油三酯水平适度降低，而消胆胺治疗使甘油三酯水平升高。辛伐他汀的耐受性优于消胆胺，后者有许多胃肠道副作用。没有患者发生严重的药物相关不良事件。
